The future of PDK1 research in cancer lies in overcoming the aforementioned challenges. Advances in precision medicine and biomarker discovery will aid in identifying patients who are most likely to benefit from PDK1-targeted therapies. Additionally, combination therapies that target multiple signaling pathways may offer a more effective approach to overcoming resistance and improving patient outcomes.
